Company Description
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome.
It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases.
The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors.
The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021.
The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Jennifer Buell |
Contact Details
Address: 149 Fifth Avenue, Suite 500 New York, New York 10010 United States | |
| Phone | 212 994 8250 |
| Website | minktherapeutics.com |
Stock Details
| Ticker Symbol | INKT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001840229 |
| CUSIP Number | 603693102 |
| ISIN Number | US6036931029 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jennifer S. Buell Ph.D. | President, Chief Executive Officer and Director |
| Dr. Garo H. Armen Ph.D. | Executive Chairman |
| Christine M. Klaskin | Treasurer and Principal Financial and Accounting Officer |
| Eleni Chantzoura Ph.D. | Director and Head of Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 18, 2025 | 8-K | Current Report |
| Jan 21, 2025 | 8-K | Current Report |
| Dec 20, 2024 | DEF 14A | Other definitive proxy statements |
| Dec 6, 2024 | PRE 14A | Other preliminary proxy statements |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 18, 2024 | 8-K | Current Report |